Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine‐activated killer cells generated from autologous spleen cells

Cancer

Volumn 58, Issue 5, 1986, Pages 1001-1006

  Okuno, Kiyotaka ^a   Takagi, Hiromi ^a   Nakamura, Tetsuhiko ^a   Nakamura, Yohsuke ^a   Iwasa, Zenji ^a   Yasutomi, Masayuki ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SENSITIVITY; FEVER; HUMAN; IMMUNOTHERAPY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER; LIVER CELL CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; THERAPY;

ADULT; AGED; ALPHA-FETOPROTEINS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; HEPATIC ARTERY; HUMANS; IMMUNIZATION, PASSIVE; INTERLEUKIN-2; KILLER CELLS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; SPLEEN; STOMACH NEOPLASMS;

EID: 0022482154     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19860901)58:5<1001::AID-CNCR2820580502>3.0.CO;2-K     Document Type: Article

References (18)

1. Adoptive immunotherapy of cancer; Accomplishments and prospects
2. Adoptive autoimmunotherapy cytotoxic effect of an autologous long‐term T‐cell line on malignant melanoma
3. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells
4. Lymphokine‐activated killer cell phenomenon: Lysis of natural killer‐resistant fresh solid tumor cells by interleukin 2‐activated autologous human peripheral blood lymphocytes
5. Lymphokine‐activated killer cell phenomenon: II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus‐derived lymphocytes, and natural killer cells
6. Functional characterization of the killer‐helper factor responsible for the induction of cytotoxic T lymphocytes from thymocytes, and evidence for the nature of this factor as distinct from T cell‐replacing factor (TRF) in regards to B cell triggering
7. Further clinical studies with intrahepatic arterial infusion with 5‐fluorouracil
8. Prolonged and continuous percutaneous intra‐arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary
9. Protracted arterial chemotherapy of liver tumors: An experience of 107 cases over a 12‐year period
10. Nonsystemic treatment of metastatic tumors of the liver
11. Interleukin‐2 dependent culture of cytotoxic T‐cell lines
12. Augmentation of the anti‐tumor therapeutic efficacy of long‐term cultured T lymphocytes by in vivo administration of purified interleukin 2
13. In vivo effects of murine hybridoma monoclonal antibody in a patient with T‐cell leukemia
14. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody
15. Abnormal migration of T lymphocyte clones
16. Generation of cytolytic lymphocytes to syngeneic tumor by using costimulator (Interleukin 2)
17. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors
18. Successful immunotherapy of natural killer‐resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2